Highnoon Laboratories Limited (PSX:HINOON)

Market Cap	48.62B
Revenue (ttm)	24.63B
Net Income (ttm)	3.39B
Shares Out	52.98M
EPS (ttm)	63.95
PE Ratio	14.35
Forward PE	n/a
Dividend	30.00 (3.27%)
Ex-Dividend Date	Apr 18, 2025

Volume	103,656
Average Volume	20,562
Open	904.90
Previous Close	885.32
Day's Range	880.00 - 950.00
52-Week Range	504.77 - 1,000.00
Beta	0.18
RSI	67.76
Earnings Date	Mar 7, 2025

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, respiratory, and urology; and generic products under various brands. The company serves Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, and internationally. Highnoon ...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1984
• Employees: 2,295
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HINOON

Financial Performance

In 2023, Highnoon Laboratories's revenue was 19.77 billion, an increase of 24.98% compared to the previous year's 15.82 billion. Earnings were 2.45 billion, a decrease of -1.01%.